Home›Trial›NCT05046613

🔬NCT05046613RECRUITING

Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant

Study Summary

The purpose of the study is to evaluate fetal, maternal, and infant outcomes through 12 months of age.

Conditions

Interventions / Drugs

Rimegepant Not taking Rimegepant

View on ClinicalTrials.gov ↗

Sponsor

Diversified Pharma

Study Details

Enrollment780 participants

Primary Completion—

Lead SponsorPfizer

Data Retrieved2026-04-11 02:55:53.189889+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.